Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Novel T-cell immunotherapies (chimeric antigen receptor [CAR] T cells and T-cell redirecting bispecific antibodies) are changing the treatment landscape of relapsed or refractory multiple myeloma. In this Review, the European Myeloma Network provides recommendations to optimise both safety and effic...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2025
|
| In: |
The lancet. Haematology
Year: 2025, Jahrgang: 12, Heft: 8, Pages: e635-e649 |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/S2352-3026(25)00117-6 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S2352-3026(25)00117-6 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2352302625001176 
|
| Verfasserangaben: | Niels WCJ van de Donk, Philippe Moreau, Jesús F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksac, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte LBM Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hajek, Heinz Ludwig, Carlos Fernandez de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodriguez-Otero, Kwee Yong, Leo Rasche, Evangelos Terpos, Marc S Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele, on behalf of the EMN Guidelines Committee |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949958248 | ||
| 003 | DE-627 | ||
| 005 | 20260122090454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260122s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2352-3026(25)00117-6 |2 doi | |
| 035 | |a (DE-627)1949958248 | ||
| 035 | |a (DE-599)KXP1949958248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Donk, Niels van de |d 1976- |e VerfasserIn |0 (DE-588)1251850812 |0 (DE-627)1789622182 |4 aut | |
| 245 | 1 | 0 | |a Optimising T-cell immunotherapy in patients with multiple myeloma |b practical considerations from the European Myeloma Network |c Niels WCJ van de Donk, Philippe Moreau, Jesús F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksac, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte LBM Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hajek, Heinz Ludwig, Carlos Fernandez de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodriguez-Otero, Kwee Yong, Leo Rasche, Evangelos Terpos, Marc S Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele, on behalf of the EMN Guidelines Committee |
| 264 | 1 | |c August 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 25. Juni 2025, Artikelversion: 4. August 2025 | ||
| 500 | |a Gesehen am 22.01.2026 | ||
| 520 | |a Novel T-cell immunotherapies (chimeric antigen receptor [CAR] T cells and T-cell redirecting bispecific antibodies) are changing the treatment landscape of relapsed or refractory multiple myeloma. In this Review, the European Myeloma Network provides recommendations to optimise both safety and efficacy of T-cell immunotherapy. In patients who are eligible for both CAR T-cell therapy and bispecific antibodies, we recommend using CAR T-cell therapy first due to the high response rate and durable progression-free survival, accompanied by improved quality of life. Furthermore, previous bispecific antibody treatment has a negative effect on the efficacy of CAR T-cell therapy, and there is emerging evidence that suggests that relapse after B-cell maturation antigen-directed CAR T-cell therapy can be effectively managed with bispecific antibodies. Timely referral and planning are crucial before initiating T-cell immunotherapy to optimise treatment selection, conduct adequate diagnostic tests (eg, excluding latent infections), and identify modifiable risk factors to improve clinical outcomes. Supportive care is crucial in all patients receiving T-cell immunotherapy to prevent non-relapse mortality. | ||
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a San-Miguel, Jesús F |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mateos, Maria-Victoria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zweegman, Sonja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gay, Francesca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engelhardt, Monika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mina, Roberto |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zamagni, Elena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delforge, Michel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beksac, Meral |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spencer, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schjesvold, Fredrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Driessen, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaiser, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perrot, Aurore |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wäsch, Ralph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Korst, Charlotte LBM |e VerfasserIn |4 aut | |
| 700 | 1 | |a Broijl, Annemiek |e VerfasserIn |4 aut | |
| 700 | 1 | |a Touzeau, Cyrille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manier, Salomon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hajek, Roman |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ludwig, Heinz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fernandez de Larrea, Carlos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Popat, Rakesh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rodriguez-Otero, Paula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yong, Kwee |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rasche, Leo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Terpos, Evangelos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Boccadoro, Mario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sonneveld, Pieter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Einsele, Hermann |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Haematology |d London [u.a.] : Elsevier, 2014 |g 12(2025), 8 vom: Aug., Seite e635-e649 |h Online-Ressource |w (DE-627)810540304 |w (DE-600)2802056-X |w (DE-576)420435689 |x 2352-3026 |7 nnas |a Optimising T-cell immunotherapy in patients with multiple myeloma practical considerations from the European Myeloma Network |
| 773 | 1 | 8 | |g volume:12 |g year:2025 |g number:8 |g month:08 |g pages:e635-e649 |g extent:15 |a Optimising T-cell immunotherapy in patients with multiple myeloma practical considerations from the European Myeloma Network |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S2352-3026(25)00117-6 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2352302625001176 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20260122 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 32 | ||
| 999 | |a KXP-PPN1949958248 |e 4856929070 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Niels van de","display":"Donk, Niels van de","family":"Donk"},{"given":"Philippe","role":"aut","family":"Moreau","display":"Moreau, Philippe"},{"family":"San-Miguel","display":"San-Miguel, Jesús F","given":"Jesús F","role":"aut"},{"role":"aut","given":"Maria-Victoria","display":"Mateos, Maria-Victoria","family":"Mateos"},{"role":"aut","given":"Meletios A","display":"Dimopoulos, Meletios A","family":"Dimopoulos"},{"family":"Zweegman","display":"Zweegman, Sonja","role":"aut","given":"Sonja"},{"role":"aut","given":"Francesca","display":"Gay, Francesca","family":"Gay"},{"family":"Engelhardt","display":"Engelhardt, Monika","role":"aut","given":"Monika"},{"display":"Mina, Roberto","family":"Mina","given":"Roberto","role":"aut"},{"role":"aut","given":"Elena","display":"Zamagni, Elena","family":"Zamagni"},{"display":"Delforge, Michel","family":"Delforge","given":"Michel","role":"aut"},{"display":"Beksac, Meral","family":"Beksac","role":"aut","given":"Meral"},{"given":"Andrew","role":"aut","family":"Spencer","display":"Spencer, Andrew"},{"role":"aut","given":"Fredrik","family":"Schjesvold","display":"Schjesvold, Fredrik"},{"role":"aut","given":"Christoph","family":"Driessen","display":"Driessen, Christoph"},{"given":"Martin","role":"aut","display":"Kaiser, Martin","family":"Kaiser"},{"role":"aut","given":"Aurore","family":"Perrot","display":"Perrot, Aurore"},{"given":"Ralph","role":"aut","display":"Wäsch, Ralph","family":"Wäsch"},{"given":"Charlotte LBM","role":"aut","family":"Korst","display":"Korst, Charlotte LBM"},{"role":"aut","given":"Annemiek","family":"Broijl","display":"Broijl, Annemiek"},{"role":"aut","given":"Cyrille","family":"Touzeau","display":"Touzeau, Cyrille"},{"display":"Manier, Salomon","family":"Manier","role":"aut","given":"Salomon"},{"role":"aut","given":"Roman","display":"Hajek, Roman","family":"Hajek"},{"family":"Ludwig","display":"Ludwig, Heinz","role":"aut","given":"Heinz"},{"display":"Fernandez de Larrea, Carlos","family":"Fernandez de Larrea","role":"aut","given":"Carlos"},{"display":"Popat, Rakesh","family":"Popat","given":"Rakesh","role":"aut"},{"family":"Musto","display":"Musto, Pellegrino","given":"Pellegrino","role":"aut"},{"display":"Rodriguez-Otero, Paula","family":"Rodriguez-Otero","role":"aut","given":"Paula"},{"display":"Yong, Kwee","family":"Yong","role":"aut","given":"Kwee"},{"role":"aut","given":"Leo","family":"Rasche","display":"Rasche, Leo"},{"display":"Terpos, Evangelos","family":"Terpos","role":"aut","given":"Evangelos"},{"given":"Marc-Steffen","role":"aut","family":"Raab","display":"Raab, Marc-Steffen"},{"family":"Boccadoro","display":"Boccadoro, Mario","given":"Mario","role":"aut"},{"given":"Pieter","role":"aut","display":"Sonneveld, Pieter","family":"Sonneveld"},{"role":"aut","given":"Hermann","display":"Einsele, Hermann","family":"Einsele"}],"language":["eng"],"title":[{"title":"Optimising T-cell immunotherapy in patients with multiple myeloma","title_sort":"Optimising T-cell immunotherapy in patients with multiple myeloma","subtitle":"practical considerations from the European Myeloma Network"}],"note":["Online verfügbar: 25. Juni 2025, Artikelversion: 4. August 2025","Gesehen am 22.01.2026"],"origin":[{"dateIssuedDisp":"August 2025","dateIssuedKey":"2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"titleAlt":[{"title":"The lancet <London> / Haematology"}],"part":{"extent":"15","volume":"12","pages":"e635-e649","year":"2025","text":"12(2025), 8 vom: Aug., Seite e635-e649","issue":"8"},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Optimising T-cell immunotherapy in patients with multiple myeloma practical considerations from the European Myeloma NetworkThe lancet. Haematology","title":[{"title":"The lancet","partname":"Haematology","title_sort":"lancet"}],"note":["Gesehen am 27.11.14"],"origin":[{"dateIssuedKey":"2014","publisher":"Elsevier","dateIssuedDisp":"2014-","publisherPlace":"London [u.a.]"}],"pubHistory":["1.2014 -"],"id":{"eki":["810540304"],"zdb":["2802056-X"],"issn":["2352-3026"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"810540304"}],"recId":"1949958248","physDesc":[{"extent":"15 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Niels WCJ van de Donk, Philippe Moreau, Jesús F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksac, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte LBM Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hajek, Heinz Ludwig, Carlos Fernandez de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodriguez-Otero, Kwee Yong, Leo Rasche, Evangelos Terpos, Marc S Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele, on behalf of the EMN Guidelines Committee"]},"id":{"eki":["1949958248"],"doi":["10.1016/S2352-3026(25)00117-6"]}} | ||
| SRT | |a DONKNIELSVOPTIMISING2025 | ||